Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
NIH-supported study shows this treatment resulted in higher rates of illicit opioid abstinence than current standard of care
2026-03-16
(Press-News.org) In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue (sublingual), one of the standard methods of treatment. Additionally, serious adverse events were less common in those receiving extended-release treatment. The findings, which support the use of this formulation of buprenorphine for treating OUD during pregnancy, were published in JAMA Internal Medicine.
“These findings are clinically valuable for they show us that this injectable extended-release buprenorphine formulation is safe to use in pregnancy and results in better opioid abstinence outcomes compared to sublingual buprenorphine,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “This is especially relevant in the context of the ongoing opioid overdose crisis and public health emergency.”
Illicit opioid use and untreated OUD can have dire consequences during pregnancy, including risk of fatal overdose for the mother and the development of neonatal opioid withdrawal syndrome (NOWS) and other adverse consequences for the baby. Treating OUD in pregnancy with sublingual buprenorphine is effective, but it has disadvantages, including risk of misuse, potentially poor adherence, and daily fluctuating blood levels known as peak-trough effects that may inadequately mitigate opioid-related cravings and withdrawal, leading to continued opioid use. The researchers in this study wanted to see if using a weekly formulation of subcutaneous (under-the-skin), extended-release buprenorphine injections during pregnancy—with the option of a monthly formulation for postpartum participants who were not breastfeeding—might promote as good or better opioid abstinence rates and NOWS outcomes.
In the multicenter trial, 140 pregnant adults were randomized to receive either injectable extended-release or sublingual buprenorphine (with or without naloxone). The trial, supported by the NIDA Clinical Trials Network as part of the NIH Helping to End Addiction Long-term ® Initiative (NIH HEAL Initiative®), was the first randomized trial testing extended-release buprenorphine for OUD in pregnancy and postpartum.
The researchers found that rates of illicit opioid abstinence during pregnancy, as measured by urine drug screens, were significantly higher for those receiving weekly extended-release buprenorphine and were non-inferior postpartum compared to participants receiving sublingual buprenorphine. While the percentage of participants experiencing non-serious maternal adverse events did not differ between the types of treatments, they were more commonly rated as medication-related in the extended-release group during pregnancy. Serious maternal adverse events were less common in the extended-release group throughout the trial. NOWS outcomes did not differ between the treatment groups.
“We knew that injectable extended-release buprenorphine leads to superior rates of illicit opioid abstinence in non-pregnant adults, but there had been no completed randomized clinical trial testing its use during pregnancy,” said principal investigator and lead author John Winhusen, Ph.D., professor of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine. “It is exciting to share the results of this trial, which have immediate clinical application: this longer-acting medication can safely and more effectively support treatment and recovery in pregnant patients.”
###
If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. To learn how to get support for mental health, drug or alcohol conditions, visit FindSupport.gov. If you are ready to locate a treatment facility or provider, you can go directly to FindTreatment.gov or call 800-662-HELP (4357).
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov.
NIH…Turning Discovery Into Health®
Reference: TJ Winhusen, et al. Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2026.0057
END
ELSE PRESS RELEASES FROM THIS DATE:
2026-03-16
BALTIMORE, MD, March 14, 2026, Dr. Thomas Hartung, Director of the Center for Alternatives to Animal Testing (CAAT) at the Johns Hopkins Bloomberg School of Public Health, has endorsed the public launch of ToxIndex, an agentic AI platform developed by Insilica Inc. that produces comprehensive, source-traceable toxicological risk assessments in just a few hours.
The launch of ToxIndex meets a critical need in chemical and drug safety, as well as in exposomics, a field of study that considers the effects of environmental exposures on human health and serves as a complement and counterpart to ...
2026-03-16
Type 2 diabetes (T2D) and obesity are metabolic conditions with many causes, including overlapping and distinct genetic features. A polygenic risk score (PRS) can capture multiple genetic risk factors to provide an estimate for whether a person may develop a complex medical condition and how they might fare long-term. By integrating genetic findings from several of the world’s largest biobanks, investigators from Mass General Brigham built metabolic PRSs for predicting obesity and T2D, which outperformed existing ...
2026-03-16
Dielectric ceramic capacitors are critical components in modern electronics and pulsed power systems, prized for their ultra-fast charge–discharge capabilities and high-power density. However, their real-world application has been constrained by modest recoverable energy storage density (Wrec) and energy efficiency (η), especially under extreme operating conditions.
Now, a research team led by Professor Changzheng Hu from the College of Materials Science and Engineering at Guilin University of Technology has developed a new class of lead-free relaxor ferroelectric ceramics that overcome these limitations. By integrating high-entropy design with bandgap engineering, ...
2026-03-16
Dielectric ceramic capacitors are essential core components for electronics, smart grids and new energy vehicles, prized for their high power density. As electronic devices move toward miniaturization and intelligence, the demand for lead-free dielectric ceramics with ultrahigh recoverable energy storage density (Wrec) and high efficiency (η) is becoming increasingly urgent. Relaxor ferroelectrics (RFE) suffer from relatively large remnant polarization, while superparaelectric relaxor ferroelectrics (SPE-RFE) see ...
2026-03-16
Febrile neutropenia (FN) is a serious chemotherapy complication defined by fever (≥38.3°C) and low neutrophil count (<0.5×10⁹/L). It affects 7–8 per 1,000 cancer patients, with 9.5% mortality. FN often leads to chemotherapy delays, compromising treatment efficacy. Current standard care—antibiotics and granulocyte colony-stimulating factor (G-CSF)—faces limitations including antibiotic resistance, G-CSF side effects (bone pain, vasculitis), and refractory cases. Traditional Chinese ...
2026-03-16
Thermal barrier coatings are indispensable shields that protect the hot-end components of gas turbines and aircraft engines from extreme temperatures. Current industry-standard YSZ coatings face several critical limitations: an unstoppable phase transition that restricts operating temperatures below 1200 °C, dramatically rising thermal conductivity due to thermal radiation above 900 °C, severe corrosion by CaO–MgO–Al2O3–SiO2 (CMAS) melts, and vulnerability to moisture degradation. These combined deficiencies have driven urgent demand for next-generation TBC materials capable of sustained service at 1200–1500 °C.
High-entropy ...
2026-03-16
(Toronto, March 16, 2026) JMIR Publications is proud to announce the appointment of Dr. Sara Simblett as the new editor in chief of JMIR Neurotechnology.
Dr. Sara Simblett is a clinical academic whose work focuses on digital health innovation, patient engagement, and the integration of technology into neuropsychology and broader mental health services. Her research is translational, combining clinical psychology, implementation science, and data-driven methodologies, such as ecological momentary assessment and the use of mobile technology, to evaluate and scale digital interventions that improve ...
2026-03-16
SAN ANTONIO — March 16, 2026 — Southwest Research Institute (SwRI) has received a contract from the U.S Air Force Academy to characterize inspection methods for bolt holes in aging aircraft to inspect through bushings without removing them. Assessing bolt hole condition inspection supports wider efforts that inform repair decisions and ensure aircraft safety.
For decades, SwRI has supported the U.S. Air Force’s Aircraft Structural Integrity Program (ASIP) and the U.S. Air Force Academy Center for Aircraft Structural Life Extension ...
2026-03-16
PULLMAN, Wash. — Again and again, Washington State University professor Mesut Cicek and his colleagues fed hypotheses from scientific papers into ChatGPT and asked it to determine whether the statements had been upheld by research — whether they were true or false.
They did this with more than 700 hypotheses, repeating each query 10 times.
AI answered correctly 76.5% of the time when the experiment was run in 2024. When it was repeated in 2025, the accuracy improved to 80%. When accounting for random guessing, however, AI was only about 60% better than chance ...
2026-03-16
Nearly 1 in 5 teens in the United States is obese, putting their long-term health at serious risk. Obesity in adolescence leads to many deleterious medical conditions including diabetes, high blood pressure, sleep apnea, and mental health struggles with low self-esteem and depression.
Understanding patterns of obesity and weight-loss efforts in U.S. adolescents is critical for shaping effective clinical and public health interventions. Yet, data remain sparse on whether and how adolescents attempt to lose weight.
To explore these issues, researchers from Florida Atlantic University’s Charles E. Schmidt ...
LAST 30 PRESS RELEASES:
[Press-News.org] Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
NIH-supported study shows this treatment resulted in higher rates of illicit opioid abstinence than current standard of care
